LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LondonWallet
No Result
View All Result

These are the most expensive S&P 500 stocks heading into the second half

Chaim Potok by Chaim Potok
June 27, 2024
in Investing
These are the most expensive S&P 500 stocks heading into the second half
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter


While the artificial intelligence boom brought stocks to record highs in the first half of the year, concern has mounted that valuations are stretched. Strategists polled by CNBC Pro say that market gains in the rest of 2024 may be harder to come by , forecasting that the S & P 500 will add just 1% based on median price targets. Some market pundits have noted anxiety over valuations, saying price-earnings ratios and other yardsticks may be getting ahead of themselves. They also highlight signs of exhaustion in some formerly high-flying stocks. That forecast comes as Nvidia entered a correction earlier this week, adding to worries dating from late last year that too few stocks have participated in the latest up-move. Against this backdrop, CNBC Pro screened for some of the most expensive stocks on Wall Street, using the following criteria as a filter: Current price-earnings ratio is more than 50% higher than the stock’s 5-year average price-earnings ratio Each stock’s current forward price-earnings ratio is above the S & P 500’s forward price-earnings ratio of 21 Readers can customize their screen using the CNBC Pro Stock Screener tool here . Data in the table below is current as of Tuesday. Artificial Intelligence plays Top AI plays were among the list of expensive stocks in the S & P 500, including Broadcom , Lam Research , Intel and Super Micro Computer . All of the AI plays on the list have trailing 12-month price-earnings ratios more than double their five-year average. Beyond Nvidia, shares of Super Micro Computer and Broadcom have been two of the biggest beneficiaries of the AI boom, sporting gains of more than 188% and 42%, respectively. Each stock’s price-earnings ratio equates to a roughly 60% to 66% premium over the historical average. SMCI YTD mountain Super Micro Computer stock. Broadcom’s fiscal second-quarter results reported earlier this month surpassed Wall Street estimates for earnings and revenue, and it declared a 10-for-1 stock split. Bank of America posited that the company could soon join the likes of Nvidia with a multitrillion-dollar valuation. Super Micro Computer, meanwhile, has continued to ride the AI wave despite some weakness last month after third-quarter revenue missed analyst expectations. The stock found more upside last week after Elon Musk said that both Super Micro and Dell would provide servers to power xAI’s forthcoming supercomputer. Wariness surrounding how much higher stocks at the forefront of the AI boom can rise has grown as the stocks have become more detached from the rest of the market. At the same time, investors are beginning to wonder if the robust spending these companies are deploying on AI signals that applications will soon deliver higher profits. AVGO YTD mountain Broadcom stock. “Given the focus and architecture of generative AI technology today… truly transformative changes won’t happen quickly and few — if any — will likely occur within the next 10 years,” Massachusetts Institute of Technology professor Daron Acemoglu was quoted telling Goldman Sachs global macro analysts in a June 25 note. Eli Lilly Eli Lilly also turned up as expensive, after shares of the GLP-1 weight loss drugmaker have soared more than 54% in 2024. The stock’s trailing 12-month price-earnings ratio is also more than double its five-year average, at a 63% premium. The company continues to benefit from sky-high demand for GLP-1 drugs. Eli Lilly also saw an independent board of advisors to the U.S. Food and Drug Administration recommend its Alzheimer’s treatment donanemab , opening the door for its approval. If given the green light, the drug would be just the second treatment of its kind in the U.S., alongside Biogen’s Leqembi.



Source link

You might also like

Political risk: How Trump 2.0 is affecting investment in U.S. assets

Top Wall Street analysts suggest these 3 dividend stocks for stable income

Earnings playbook: Amazon and Alphabet headline the busiest week of the reporting period

Share30Tweet19
Previous Post

As Ethereum phishing gets harder, drainers move to TON and Bitcoin

Next Post

Sable acquires 180-home BTR scheme from Galliard and O’Shea | Property Week

Chaim Potok

Chaim Potok

Recommended For You

Political risk: How Trump 2.0 is affecting investment in U.S. assets
Investing

Political risk: How Trump 2.0 is affecting investment in U.S. assets

February 1, 2026
Top Wall Street analysts suggest these 3 dividend stocks for stable income
Investing

Top Wall Street analysts suggest these 3 dividend stocks for stable income

February 1, 2026
Earnings playbook: Amazon and Alphabet headline the busiest week of the reporting period
Investing

Earnings playbook: Amazon and Alphabet headline the busiest week of the reporting period

February 1, 2026
Flying without a Real ID? You may owe  — or more — starting Feb. 1
Investing

Flying without a Real ID? You may owe $45 — or more — starting Feb. 1

January 31, 2026
Next Post
Sable acquires 180-home BTR scheme from Galliard and O’Shea | Property Week

Sable acquires 180-home BTR scheme from Galliard and O’Shea | Property Week

Related News

5 peer-to-peer (P2P) lending platforms for borrowers and lenders

5 peer-to-peer (P2P) lending platforms for borrowers and lenders

July 15, 2023
BLUETTI’s Prime Day deals are up to 65% off with the launch of the Elite 100 V2 

BLUETTI’s Prime Day deals are up to 65% off with the launch of the Elite 100 V2 

July 8, 2025
What to expect at Caroline Ellison’s sentencing hearing

What to expect at Caroline Ellison’s sentencing hearing

September 20, 2024

Browse by Category

  • Business Finance
  • Crypto
  • Industries
  • Investing
  • jutawantoto
  • Markets
  • Opinion
  • Real Estate
  • UK

London Wallet

Read latest news about finance, business and investing

  • Contact
  • Privacy Policy
  • Terms & Conditions

© 2025 London Wallet - All Rights Reserved!

No Result
View All Result
  • Checkout
  • Contact
  • Home
  • Login/Register
  • My account
  • Privacy Policy
  • Terms and Conditions

© 2025 London Wallet - All Rights Reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?